BARD1 and breast carcinoma: A total of 1010 breast cancer patients (27.3%) and 230 ovarian cancer patients (25.8%) carried a VUS, and these were mainly in BARD1 (27.6%) and ATM (19.3%), as shown in Figure 2C and Table 2.